Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review) - Wikidata - wikimedia - TriplyDB

Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)

Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)

http://www.wikidata.org/entity/Q36643541

about

Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes Identification of a novel lysosomal trafficking peptide using phage display biopanning coupled with endocytic selection pressure Biocompatible and biodegradable fibrinogen microspheres for tumor-targeted doxorubicin delivery.Targeting Cathepsin B for Cancer Therapies.Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients.Strategies to release doxorubicin from doxorubicin delivery vehicles.Recent updates in utilizing prodrugs in drug delivery (2013-2015).Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines.Metal-Organic Polyhedron Capped with Cucurbit[8]uril Delivers Doxorubicin to Cancer Cells Simultaneous determination of doxorubicin and its dipeptide prodrug in mice plasma by HPLC with fluorescence detection.Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer.Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence Imaging.

P2860

Q26827307-6C6718D6-F65F-4B2D-B5FA-DECB4A0D44BE Q34343508-BAE26E47-6FBD-4173-BDF8-776E3153D37A Q36037022-32F1F915-9213-4720-A97E-3B3E05B58C3C Q36326605-3CE32BEF-C416-4C77-B5A6-779536A9714A Q36502689-74B3F7BC-CBD4-4573-ABD0-C86661076130 Q38643071-3BF3F770-C4DC-4F05-B4FB-451C14C4379C Q38702949-8B448AF0-B042-428A-A652-9329F8308784 Q39264057-BB5BD391-5A82-45D6-8423-02AECB198B2C Q42859704-7F284AD7-690A-4155-8631-5344F805D14D Q49218382-EDFE00AA-FEF9-4B7B-BCED-D3D297D558FE Q49425807-1D7E14BF-7351-40F4-AE28-345F681A0BF9 Q51132166-D0240B1D-8EFB-4142-A940-21B367428285

P2860

Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)

http://www.wikidata.org/entity/Q36643541

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cathepsin B-cleavable doxorubi ...... r therapy (Review)

@ast

Cathepsin B-cleavable doxorubi ...... r therapy (Review)

@en

type

label

Cathepsin B-cleavable doxorubi ...... r therapy (Review)

@ast

Cathepsin B-cleavable doxorubi ...... r therapy (Review)

@en

prefLabel

Cathepsin B-cleavable doxorubi ...... r therapy (Review)

@ast

Cathepsin B-cleavable doxorubi ...... r therapy (Review)

@en

P1433

Q36643541-FF0CF361-03C4-4B44-A934-3F1D727C511A

P1476

Q36643541-55A65413-5B55-4DF8-9197-F2AB181D9C41

P2093

Q36643541-1B86A7EE-70DA-4D34-8D9C-62478834D3AC

Q36643541-37CD06C2-9BEC-4403-91DF-1B3430A97CDD

Q36643541-874215C1-64ED-459C-BAB9-B6D5F8B3F377

P275

Q36643541-31C93F3E-2700-42A2-B9B0-865611934984

P2860

Q36643541-052FC7FB-2B05-4491-B90D-EF5F6529525D

Q36643541-0B6FC0D5-F28A-40E9-88D4-007A20A59D8B

Q36643541-0C8067C9-A463-4AA4-B72E-FD6A1D56ECB1

Q36643541-0CBB3288-C8EC-4839-A781-6E1DC6799BE4

Q36643541-0FE5D713-F3DD-4197-AEB4-301E45E8C960

Q36643541-15BFF3D8-7FBE-401B-BFAF-E72F2D71DFB6

Q36643541-1DE874E8-2872-4BF5-8643-9053FB94CF60

Q36643541-226DC8FB-1ED0-4CB3-B41F-FB537173B174

Q36643541-25BA7650-3293-442D-826A-64F9A50AB560

Q36643541-279BF929-CDC8-4B81-8BFA-782FCE045FA1

P304

Q36643541-589CA756-5C63-492A-97EB-39E7A3E25ADD

P31

Q36643541-26239EE8-8F77-48AF-A146-2C7D353D5049

Q36643541-3F509F4E-D269-4772-9883-AD5B24173D62

P356

Q36643541-3EA23551-F76B-41A4-B336-9F984692EF77

P433

Q36643541-CE01036D-08D3-4AC3-95BC-F1C3D4679A39

P478

Q36643541-DAF3B161-CF92-4F6C-BF45-DB4B04DCED22

P577

Q36643541-793B4AED-CF1F-4257-8C0D-40FA9CE07B2A

Q36643541-F30828CE-F611-42EA-85C5-539ACB7CCDDC

P5875

Q36643541-A8383E6E-E780-4AC9-ACD9-6C400382882B

P698

Q36643541-41716754-03CA-4599-AE89-7EB0DDA4D430

P921

Q36643541-84FDD7EC-71DB-40C7-B28B-7145AE3FCAE5

Q36643541-AB333031-F4CE-49F1-A971-6EF979778AFF

Q36643541-EB8337FD-01CA-4D22-8DF6-C8AEAFCC8A07

Q36643541-FC7D8BEE-D789-49EC-8948-7575025B21B3

P932

Q36643541-9BE3F9CE-A860-49B3-9CE2-9959A4D5B8D5

P356

P1433

International Journal of Oncology

P1476

Cathepsin B-cleavable doxorubi ...... r therapy (Review)

@en

P2093

Li-Hua Shao

http://www.w3.org/2001/XMLSchema#string

Yan Li

http://www.w3.org/2001/XMLSchema#string

Yan-Jun Zhong

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma

Multidrug resistance in cancer: role of ATP-dependent transporters

Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat

Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates.

Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.

Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice.

Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates.

Cell surface complex of cathepsin B/annexin II tetramer in malignant progression.

P304

373-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/IJO.2012.1754

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234067636

http://www.w3.org/2001/XMLSchema#string

P698

23291656

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

polycyclic compound

P932

3583876

http://www.w3.org/2001/XMLSchema#string